NCT02815267View on ClinicalTrials.gov

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

PHASE3CompletedINTERVENTIONAL
Enrollment

466

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 13, 2017

Study Completion Date

October 13, 2017

Conditions
Acne Vulgaris
Interventions
DRUG

FMX-101, 4% minocycline foam

FMX-101, 4% minocycline foam applied topically once daily for 12 weeks

DRUG

Vehicle Foam

Vehicle foam applied topically once daily for 12 weeks

Trial Locations (31)

10012

New York

10075

New York

20037

Washington D.C.

20850

Rockville

26330

Bridgeport

27262

High Point

31406

Savannah

32771

Sanford

33015

Miami

33027

Miramar

33174

Miami

33437

Boynton Beach

35205

Birmingham

37130

Murfreesboro

43213

Columbus

47713

Evansville

48706

Bay City

60181

Oakbrook Terrace

68114

Omaha

70006

Metairie

75024

Plano

75234

Dallas

78229

San Antonio

84088

West Jordan

89117

Las Vegas

92835

Fullerton

94538

Fremont

97030

Gresham

06484

Shelton

02919

Johnston

Unknown

San Cristóbal

All Listed Sponsors
lead

Vyne Therapeutics Inc.

INDUSTRY

NCT02815267 - A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne | Biotech Hunter | Biotech Hunter